STOCK TITAN

TransMedics to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of the management team will be virtually participating in two upcoming investor conferences. TransMedics will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020, followed by the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020.

Event: Oppenheimer Fall MedTech Summit
Format: 1x1 Meetings
Date: Thursday, November 12, 2020

Event: Canaccord Genuity Virtual MedTech & Diagnostics Forum
Format: 1X1 Meetings
Date: Thursday, November 19, 2020

As management will be participating in 1x1 meeting only, no webcasts will be available.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-participate-in-upcoming-virtual-investor-conferences-301163404.html

SOURCE TransMedics Group, Inc.

TransMedics Group, Inc.

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Stock Data

4.20B
31.55M
3.62%
111.73%
18.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ANDOVER

About TMDX

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.